Gene · 862
Papers4,591
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
381 to 400 of 4,591
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Imatinib blocks tyrosine phosphorylation of Smad4 and restores TGF-β growth-suppressive signaling in BCR-ABL1-positive leukemia. | Signal Transduct Target Ther | 2023 | 36959211 | PubTator, text mining | PubMed |
| ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias. | Blood Cancer J | 2023 | 36959186 | PubTator, text mining | PubMed |
| [Treatment responses, outcomes, and prognostic factors associated with them in patients with secondary acute myeloid leukemia]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 36948866 | PubTator, text mining | PubMed |
| Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study. | Blood Adv | 2023 | 36939402 | PubTator, text mining | PubMed |
| RNA sequencing of myeloid sarcoma, shed light on myeloid sarcoma stratification. | Cancer Med | 2023 | 36916780 | PubTator, text mining | PubMed |
| New, Low-Molecular Weight Chemical Compounds Inhibiting Biological Activity of Interleukin 15. | Molecules | 2023 | 36903533 | PubTator, text mining | PubMed |
| Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication. | Int J Mol Sci | 2023 | 36902217 | PubTator, text mining | PubMed |
| Expression of Non-T Cell Activation Linker (NTAL) in Jurkat Cells Negatively Regulates TCR Signaling: Potential Role in Rheumatoid Arthritis. | Int J Mol Sci | 2023 | 36902005 | PubTator, text mining | PubMed |
| Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study. | Cancers (Basel) | 2023 | 36900400 | PubTator, text mining | PubMed |
| Pediatric Myeloid Sarcoma, More than Just a Chloroma: A Review of Clinical Presentations, Significance, and Biology. | Cancers (Basel) | 2023 | 36900239 | PubTator, text mining | PubMed |
| Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review. | Cancers (Basel) | 2023 | 36900154 | PubTator, text mining | PubMed |
| RNA demethylase ALKBH5 promotes tumorigenesis of t (8;21) acute myeloid leukemia via ITPA m6A modification. | Biomark Res | 2023 | 36899424 | PubTator, text mining | PubMed |
| RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development. | Leukemia | 2023 | 36894620 | PubTator, text mining | PubMed |
| Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells. | Cell Rep Med | 2023 | 36889320 | PubTator, text mining | PubMed |
| Therapy-related core binding factor acute myeloid leukemia. | Int J Hematol Oncol | 2023 | 36874378 | PubTator, text mining | PubMed |
| Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia. | Front Pediatr | 2023 | 36873635 | PubTator, text mining | PubMed |
| A case report of sudden cardiac arrest and torsade de pointes induced by the second-generation tyrosine kinase inhibitor dasatinib combined with fluconazole. | Front Cardiovasc Med | 2023 | 36873392 | PubTator, text mining | PubMed |
| DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t(8;21) acute myeloid leukemia. | Clin Epigenetics | 2023 | 36864492 | PubTator, text mining | PubMed |
| Melatonin promotes differentiation and apoptosis of AML1-ETO-positive cells. | Bull Cancer | 2023 | 36863921 | PubTator, text mining | PubMed |
| A Phase I Trial of Allogeneic γδ T Lymphocytes From Haploidentical Donors in Patients With Refractory or Relapsed Acute Myeloid Leukemia. | Clin Lymphoma Myeloma Leuk | 2023 | 36863897 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/862/papers?page=20